Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
Aya Futamura, Ryo Suzuki, Yunoshin Tamura, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 13, pp. 115489-115489
Closed Access | Times Cited: 15

Showing 15 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 72
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design
Yong‐Jin Wu, Nicholas A. Meanwell
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 9786-9874
Closed Access | Times Cited: 50
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer’s disease and Parkinson’s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia
Jean‐Philippe Surivet, Elise M. Jacob, Melanie Keßler, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118132-118132
Closed Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
Makoto Uchiyama, Daiji Kambe, Yumiko Imadera, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2143-2154
Open Access | Times Cited: 13
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
A comprehensive review of discovery and development of drugs discovered from 2020–2022
Usman Shareef, Aisha Altaf, Madiha Ahmed, et al.
Saudi Pharmaceutical Journal (2023) Vol. 32, Iss. 1, pp. 101913-101913
Open Access | Times Cited: 5
Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs
Jean‐Philippe Surivet, Melanie Keßler, Catherine Vaillant, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 112, pp. 117892-117892
Closed Access | Times Cited: 1
Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies
Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera, et al.
Basic & Clinical Pharmacology & Toxicology (2023) Vol. 133, Iss. 5, pp. 576-591
Open Access | Times Cited: 3
The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
Roberta Celli, Gilles van Luijtelaar
Current Neuropharmacology (2021) Vol. 20, Iss. 7, pp. 1254-1260
Open Access | Times Cited: 6
Orexants, Orexin Receptor Antagonists: Novel Therapeutic Agents for Insomnia Disorder
Akshitha Kandukuri, Haritha Pasupulati, Satyanarayana SV Padi
International Neuropsychiatric Disease Journal (2024) Vol. 21, Iss. 6, pp. 92-108
Open Access
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2022
Matthew L. Condakes, Jennifer Jiang, David W. Lin, et al.
Medicinal chemistry reviews (2023), pp. 577-592
Closed Access
Page 1

Scroll to top